Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy

NCT07728812 · Not yet recruiting

Last updated 2026-09-22

This clinical trial is testing whether a test called MyPhenome-RX, which analyzes genes and metabolism, can help doctors choose the best weight-loss medication for adults with obesity or overweight.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 424 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-09 · est. completion 2029-01

What this study is testing ClinicalTrials.gov NCT07728812 ↗

Description as written by the study sponsor.

A pragmatic, randomized, parallel-arm, controlled study of weight loss outcomes using AOMs guided by MyPhenome test.

Treatments tested

Genetic Test also known as MyPhenome Test Genetic

The MyPhenome test is a genetic and clinical assessment that classifies individuals into biologically defined obesity phenotypes to guide personalized treatment. Using a saliva DNA sample combined with brief clinical inputs, the test predicts whether a patient has abnormalities in high CTSGRS ("Hungry Brain"), low CTSGRS ("Hungry Gut"), or hedonic eating ("Emotional Hunger").
Anti-Obesity Medication (AOM) treatment Drug

Available AOMs will be: GLP-1 Receptor Agonists (semaglutide or tirzepatide), Phentermine-Topiramate ER, and naltrexone-bupropion SR

Main thing measured	Total Body Weight Loss (TBWL) at 6 Months %
Sponsor	Phenomix Sciences
Conditions studied	Obesity & Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07728812 ↗